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Abstract 23 
Phenethylamine-based designer drugs are prevalent within the new psychoactive substance 24 
market. Characterisation of their metabolites is important in order to identify suitable 25 
biomarkers which can be used for better monitoring their consumption. Careful design of in 26 
vitro metabolism experiments using subcellular liver fractions will assist in obtaining reliable 27 
outcomes for such purposes. The objective of this study was to stepwise investigate the in 28 
vitro human metabolism of seven phenethylamine-based designer drugs using individual 29 
families of enzymes. This included para-methoxyamphetamine, para-30 
methoxymethamphetamine, 4-methylthioamphetamine, N-methyl-benzodioxolylbutanamine, 31 
benzodioxolylbutanamine, 5-(2-aminopropyl)benzofuran and 6-(2-aminopropyl)benzofuran. 32 
Identification and structural elucidation of the metabolites was performed using liquid 33 
chromatography-quadrupole-time-of-flight mass spectrometry. The targeted drugs were 34 
mainly metabolised by cytochrome P450 enzymes via O-dealkylation as the major pathway, 35 
followed by N-dealkylation, oxidation of unsubstituted C atoms and deamination (to a small 36 
extent). These drugs were largely free from Phase II metabolism. Only a limited number of 37 
metabolites were found which was consistent with the existing literature for other 38 
phenethylamine-based drugs. Also, the metabolism of most of the targeted drugs progressed 39 
at slow rate. The reproducibility of the identified metabolites was assessed through 40 
examining formation patterns using different incubation times, substrate and enzyme 41 
concentrations. Completion of the work has led to a set of metabolites which are 42 
representative for specific detection of these drugs in intoxicated individuals and also for 43 
meaningful evaluation of their use in communities by wastewater-based drug epidemiology.  44 
 45 
Keywords: new psychoactive substances, metabolite characterisation, high-resolution mass 46 
spectrometry, wastewater-based epidemiology, LC-QTOF-MS analysis47 
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1. Introduction  51 
In recent years, there has been a clear increasing trend in the production and use of new 52 
psychoactive substances (NPS), internationally [1]. NPS are considered as substances that are 53 
not under the control of the 1961 Single Convention on Narcotic Drugs or the 1971 54 
Convention on Psychotropic Substances but which may pose a threat to public health [1-3]. 55 
There are many different families of NPS, such as phenethylamines, cathinones, piperazines, 56 
and synthetic cannabinoids [2]. In the global NPS market, the number of phenethylamine 57 
derivatives was ranked as the second highest and accounted for about 23% of the total 58 
number of reported NPS in 2009–2012 [2]. To circumvent legislative band, these 59 
phenethylamine-based designer drugs are typically chemically modified from the molecular 60 
structure of classical phenethylamine-based illicit drugs, such as amphetamines and 3,4-61 
methylenedioxymethamphetamine (MDMA), and still maintain amphetamine- and/or 62 
MDMA-like physiological effects. The description of a substance as an NPS does not 63 
necessarily mean it is an entirely novel substance, but can also reflect recent increased 64 
availability on the drug market [1-3]. For instance, para-methoxymethamphetamine 65 
(PMMA), first synthesised in the late 1930s, emerged on the drug market in 2011-2013 and 66 
then appeared again recently causing several fatal intoxication cases in England, the 67 
Netherlands and Australia [4-6].  68 
Identification of NPS and their specific metabolites in human samples (e.g. serum, urine 69 
and/or saliva) is critical in forensic and clinical toxicology for provision of intoxication 70 
evidence. Also, research related to determining NPS metabolites is beneficial to the emerging 71 
field of wastewater-based drug epidemiology, in which specific drug metabolites are 72 
measured in wastewater to back-estimate the use of these substances in communities [7, 8]. A 73 
few recent studies have analysed raw wastewater samples for some phenethylamine-based 74 
designer drugs to understand their use in the communities [9-13]. Monitoring metabolised 75 
drug residues in addition to the parent drug could improve efforts to determine the extent of 76 
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the population use of these substances, especially when the parent drug concentrations in 77 
wastewater are low or below the sensitivity of analytical methods. 78 
Due to the ethical limitation on studying in vivo drug metabolism in humans, an in vitro 79 
approach has been proposed to offer a relatively efficient and direct alternative [14]. The 80 
approach usually involves: (a) incubation of the NPS of interest with pooled human liver 81 
microsomes (HLM) for an overview of metabolism (rather than particular types of 82 
isoenzymes to understand specific metabolic processes); (b) using high resolution mass 83 
spectrometry (HRMS) to screen for all metabolites of the selected NPS; (c) elucidation of the 84 
structure of individual metabolites based on its accurate mass, MS/MS fragmentation, 85 
isotopic patterns and values of double bond equivalent. Liquid chromatography (LC) 86 
combined with HRMS such as quadrupole-time-of-flight MS (QTOF-MS) has been 87 
recognised as one of the most robust and widely applied techniques for identifying drug 88 
metabolites in in vivo and in vitro matrices, facilitating discovery of NPS metabolites [15, 89 
16]. Together, LC-HRMS with careful in vitro experimental designs such as using multiple 90 
incubation time points, repeating the experiments and/or using individual enzyme families to 91 
assess specific (groups of) metabolites, the reliability of the in vitro metabolism data can be 92 
enhanced.  93 
This study selected seven phenethylamine-based designer drugs, including para-94 
methoxyamphetamine (PMA), PMMA, 4-methylthioamphetamine (4-MTA), N-methyl-95 
benzodioxolylbutanamine (MBDB), benzodioxolylbutanamine (BDB), 5-(2-96 
aminopropyl)benzofuran (5-APB) and 6-(2-aminopropyl)benzofuran (6-APB) (Fig. 1) to 97 
assess its human in vitro metabolism. These drugs are commonly considered as NPS, except 98 
for PMA and 4-MTA which were listed on the 1971 Convention on Psychotropic Substances 99 
as of September 2013. Also, a few of them including MBDB, 4-MTA and PMMA have been 100 
included in the Risk Assessment Reports of the European Monitoring Centre for Drugs and 101 
Drug Addiction [17]. The rationale for this study is based on the fact that there is a lack of a 102 
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clear understanding of human in vitro metabolites for these drugs; as previous related in vitro 103 
studies have been limited to a focus on understanding what types of isoenzymes participate in 104 
specific metabolism processes [18-23], and also that there have been no studies performed for 105 
the screening and structural elucidation of potential in vitro metabolites of these drugs using 106 
LC-HRMS. Furthermore, no comparisons of human in vitro metabolism for these drugs, 107 
which are closely related in structure, have ever been made under the same experimental 108 
conditions.  109 
Therefore, the main objective of this study was to screen for potential in vitro 110 
metabolites of these designer drugs to be formed in HLM using untargeted analysis with LC-111 
QTOF-MS. Hence, HLM as an enzyme cocktail was applied, instead of selected types of 112 
isoenzymes [18-23], to generate all the possible cytochrome P450 metabolites. Also, this 113 
study aimed to assess the in vitro metabolism of these drugs in a stepwise experimental 114 
design with individual enzyme family preparations, and to characterise their potential 115 
metabolites, propose and compare their respective metabolic pathways.   116 
 117 
2. Materials and methods 118 
2.1. Chemicals and reagents 119 
Chemical standards for PMA, PMMA, 4-MTA, MBDB, BDB, 5-APB and 6-APB were 120 
obtained from LGC Standards SARL (Molsheim, France) and Cerilliant (Round Rock, Texas, 121 
USA) at the concentration of 1 mg/mL in methanol or acetonitrile. The internal standard, 122 
theophylline, was obtained as powder (anhydrous, purity>99%) from Sigma-Aldrich 123 
(Diegem, Belgium). Pooled human liver microsomes (HLM; mix gender, n=50) were 124 
purchased from Tebu-bio (Boechout, Belgium). Pooled human liver cytosol (HLCYT; mix 125 
gender, n=50), chemical standards for 2,6-uridinediphosphate glucuronic acid (UDPGA), 126 
alamethicin (neat, purity>99%),  3'-phosphoadenosine-5'-phosphosulfate (PAPS; neat, 127 
purity>60%) lithium salt hydrate, 4-nitrophenol (4-NP), 4-nitrophenol-glucuronide (4-NP-128 
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Gluc; neat, purity>99%), 4-nitrophenol-sulfate (4-NP-Sulf; neat, purity>99%), naphthol-129 
glucuronide (Naphth-Gluc; neat, purity>99%),  5-bromo-4-chloro-3-indolyl sulfate (Indolyl-130 
Sulf; neat, purity>99%) and NADPH (neat, purity>99%) were purchased from Sigma-131 
Aldrich (Diegem, Belgium). Ultrapure water was prepared using a Purelab flex water system 132 
by Elga (Tienen, Belgium). Acetonitrile, methanol, ammonium hydroxide, hydrochloric acid 133 
and ammonium acetate were purchased from Merck (Darmstadt, Germany). All organic 134 
solvents were HPLC grade or higher.  135 
2.2. Tiered approaches on in vitro drug metabolism 136 
In this study, a two-tiered approach for investigating Phase I and Phase II in vitro drug 137 
metabolism was followed (Fig. 2). The purpose of tier I was to screen for the major 138 
metabolites formed and the family of enzymes involved in their formation, in a similar 139 
manner to the typical practice for in vitro metabolism studies. Tier I consisted of two parts, 140 
tier-IA and -IB. In tier IA, a direct metabolism of the drugs of interest was investigated, in 141 
which Phase I metabolites and direct Phase II metabolites of the parent drug (when possible 142 
to be formed) were screened. This allowed investigation of direct drug metabolism mediated 143 
separately by Phase I and Phase II enzymes. After that, tier IB was employed to investigate 144 
the Phase II metabolism of Phase I metabolites detected in tier IA, providing information on 145 
the formation of secondary metabolites. Tier II aimed to assess the consistency and 146 
reproducibility of the metabolite formed in tier I and to determine the major, intermediate and 147 
minor metabolites by monitoring over various incubation times (10, 20, 40, 60, and 90 min), 148 
enzyme concentrations (0.2, 0.4, 0.6, and 0.8 mg/mL) and substrate concentrations (1, 3, 5, 149 
and 10 µM).  150 
2.3. In vitro drug metabolism assays  151 
For tier IA samples focusing on cytochrome P450 (CYP) enzymes, the reaction mixture 152 
(final volume: 1 mL), consisting of 100 mM phosphate buffer (pH 7.4), HLM (final 153 
concentration: 0.5 mg/mL) and the substrate (final concentration: 10 µM) was pre-incubated 154 
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for 5 min in a shaking water bath at 37 °C. The reaction was initiated by addition of 10 µL of 155 
NADPH solution (final concentration: 1 mM) in the phosphate buffer. To keep the NADPH 156 
concentration saturated, an extra aliquot was added every hour. To stop the reaction after 2 h, 157 
250 µL of an ice-cold acetonitrile solution containing 1% formic acid and 5.0 µg/mL of 158 
theophylline (used as internal standard) was added to each sample, which was then vortex-159 
mixed for 30 s and centrifuged at 8,000 rpm for 5 min. The supernatant was then transferred 160 
to a glass tube, and concentrated to 200 µL under a gentle stream of nitrogen gas at 60 °C. A 161 
20 µL aliquot of acetonitrile was then added to the extract before transferring it to a HPLC 162 
vial for analysis. For tier IA samples focusing on uridinediphosphate glucuronic acid 163 
transferase (UGT) enzymes, the reaction mixture was prepared as described above for CYP 164 
enzyme samples, but adding a 10 µL aliquot (final concentration: 10 µg/mL) of alamethicin 165 
(for opening the pore of microsomal inner lumen, where UGTs are expressed) dissolved in 166 
dimethyl sulfoxide before pre-incubating the samples in the water bath. Also, the cofactor 167 
UDPGA was used instead of NADPH, but at the same final concentration (1 mM). An aliquot 168 
of UDPGA was added to the reaction mixture every hour, similarly to NADPH in the CYP 169 
experiments. In tier IA samples focusing on sulfotransferase (SULT) enzymes, the reaction 170 
mixture was prepared as described above for CYP enzyme samples, but using HLCYT (final 171 
concentration: 0.5 mg/mL) instead of HLM and using PAPS instead of NADPH as the 172 
cofactor at the same final concentration (1 mM). An aliquot of PAPS was added to the 173 
reaction mixture every hour. Samples were then processed as described above for CYP 174 
enzyme samples.  175 
In tier IB, formation of glucuronidated and sulfated metabolites of the Phase I 176 
metabolites produced in tier IA experiments was investigated in two major steps. First, Phase 177 
I metabolites of the drug of interest were enzymatically produced as described in tier IA for 178 
three hours. The reaction was quenched by keeping the samples on ice for 5 min, followed by 179 
centrifugation at 8,000 rpm for 5 min. Then, 940 µL of the supernatant, containing the 180 
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fraction of parent drug and its metabolites generated by CYP enzymes, was transferred to a 181 
new tube which contained a fresh aliquot of pooled HLM or HLCYT (final concentration: 0.5 182 
mg/mL) for the samples investigating UGT or SULT mediated metabolism, respectively. 183 
Alamethicin and the appropriate cofactors were added at the concentrations and time intervals 184 
described above for tier IA samples. The samples were incubated for two hours and prepared 185 
as described above.  186 
In the tier II experiments, three different sets of samples were prepared. In the first set, 187 
the reaction mixture (1 mL) consisted of 100 mM phosphate buffer, pooled HLM (0.8 188 
mg/mL) and the substrate (10 µM). The reaction was initiated by addition of NADPH, and 189 
stopped after 10, 20, 40, 60, and 90 min. In the second set, the reaction mixture consisted of 190 
100 mM phosphate buffer, pooled HLM at different total protein concentrations (final 191 
concentrations: 0.2, 0.4, 0.6, and 0.8 mg/mL) and a constant concentration of the substrate 192 
(10 µM). The reaction was initiated by addition of NADPH and was stopped after 90 min. In 193 
the third set, the reaction mixture consisted of 100 mM phosphate buffer, pooled HLM at a 194 
constant protein concentration (0.8 mg/mL) and the substrate at different concentrations (final 195 
concentrations: 1, 3, 5, and 10 µM). The reaction was initiated by addition of NADPH and 196 
was stopped after 90 min. The reaction was quenched and the samples were prepared as 197 
described in tier IA section above.  198 
Positive and negative control samples for each family of enzymes of interest were 199 
routinely prepared. In the positive control samples for UGT and SULT activity, 4-nitrophenol 200 
was selected as the substrate and the formation of 4-nitrophenol-sulfate and 4-nitrophenol-201 
glucuronide, respectively, was monitored. Samples were prepared as described in the tier IA 202 
section above. No positive control samples for CYP activity were prepared, because data 203 
about the catalytic activity of major human liver CYPs was provided by the HLM vendor. 204 
Three different negative control samples were prepared by omitting the enzymes, the 205 
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substrate, or the cofactor in the reaction mixture. The negative control samples for CYP, 206 
UGT and SULT activity were prepared as described in tier I section above.  207 
2.4. LC-QTOF-MS analysis 208 
Samples were analysed by a LC-QTOF-MS system which consisted of a 1290 Infinity 209 
LC (Agilent Technologies) connected to a 6530 Accurate-Mass QTOF-MS (Agilent 210 
Technologies). Chromatographic separation of the extracts was achieved using a C8 Zorbax 211 
Eclipse Plus column (150 X 2.1 mm, 3.5 µm, Agilent Technologies) with a mobile phase 212 
composition of 5 mM ammonium acetate in ultrapure water (A) and acetonitrile (B) at 40°C. 213 
The gradient program was as follows: 2% B for the first 5 min followed by linear increase of 214 
B from 2 to 22% from 5 to 25 min and from 22 to 80% from 25 to 26 min. Solvent B was 215 
maintained at 80% for 4 min, decreased to 2% from 30 to 30.5 min and kept at 2% from 30 to 216 
40 min to re-equilibrate the column. The total run time was 40 min per sample. The flow rate 217 
was 0.2 mL/min with an injection volume of 2 µL.  218 
The acceptable mass accuracy (within ±2 ppm) of the QTOF-MS was calibrated before 219 
each analysis using a reference solution for scanning up to 1700 mass-to-charge ratio (m/z) 220 
with extended dynamic range (2 GHz). Samples were analysed using positive and negative 221 
electrospray ionisation (+/-ve ESI) modes individually, with the fragmentor voltage at 300 V 222 
and gas temperature 325 °C. The QTOF-MS was set to acquire m/z ranging between 50 and 223 
1000 amu at a scan rate of 2.5 spectra per s (i.e. 400 ms/spectrum). The auto-MS/MS function 224 
was used to obtain MS/MS spectra of precursor ions using three different collision energies 225 
(10, 20 and 40 eV). Precursor ions were targeted if ion abundances exceeded the threshold of 226 
2000 with a maximum of three precursor ions per cycle.. The QTOF-MS was set to scan 227 
MS/MS m/z from 50 to 500 amu. To avoid over-fragmentation of the same precursor ion, an 228 
active exclusion function was set to exclude the precursor ions after every two spectra and 229 
release it after 0.2 min. During analysis, the reference mass standard solution (commercially 230 
available from Agilent) was constantly infused onto the QTOF-MS for monitoring and 231 
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measuring its mass accuracy with the reference masses of 121.0508 and 922.0097 for +ve 232 
ESI and of 119.0352 and 980.0152 for -ve ESI. 233 
2.5. Data analysis   234 
Two different approaches were used to assist the interpretation of the potential in vitro 235 
metabolites formed. For approach 1, potential Phase I metabolites were predicted based on 236 
authors’ knowledge considering (a) the molecular structure of the drug, (b) the family of 237 
enzymes that might be able to metabolise it and (c) the type of reactions that these families of 238 
enzymes are known to catalyse. Once the Phase I metabolites were experimentally 239 
determined (tier IA experiments), the families of Phase II enzymes that might be able to 240 
further metabolise them were identified and the structures of the Phase II metabolites were 241 
predicted. For approach 2, possible metabolites were estimated using metabolism-specific 242 
software (Nexus v1.5, Lhasa Limited), in which the chemical structure of the drug, the 243 
species of interest (i.e. humans), the enzyme families and a minimum likelihood of metabolite 244 
formation (i.e. “equivocal”) were used for prediction. The prediction was conducted up to 245 
tertiary metabolites and for a maximum of 100 metabolites. The two approaches were 246 
independently applied to the same acquired raw data file, allowing determinations of their 247 
consistency, for better understanding the potential in vitro metabolites generated. The 248 
approach of data analysis has been previously applied in our team for assessing human in 249 
vitro metabolism of environmental contaminants [24, 25] and also recently shown feasible for 250 
evaluating in vitro data on human drug metabolism with in silico methods[26].  251 
The chromatographic features of each compound, such as the retention time and peak 252 
area counts, were obtained from the extracted ion chromatograms. To confirm the 253 
identification of a metabolite, the following criteria were applied: (a) the measured molecular 254 
m/z of the precursor ion and the product ions should be respectively within 10 and 25 ppm of 255 
its theoretical value (higher mass tolerances taken into account lower sensitivities with small 256 
amounts of product ions); (b) the isotopic patterns should be overlaid at least 75% with the 257 
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predicted ones; (c) the measured double bond equivalent (DBE) value should match with the 258 
postulated structure; (d) the absence of the possible metabolite at the same retention time in 259 
all the negative control samples; (e) the proposed chemical structure of the detected 260 
metabolite has to be logical considering the chemical structure of the substrate and the 261 
reactions that the family of enzymes under investigation is able to catalyse; and (f) the 262 
retention time of the detected metabolites should not be higher than that of the parent drug. 263 
Tier II data are presented as the response value, which was calculated as the peak area ratio of 264 
the metabolite or the parent drug to the internal standard (theophylline) for compensating 265 
inter-sample and instrumental variability during analysis.    266 
 267 
3. Results  268 
3.1. PMA and PMMA 269 
In tier IA samples, the only metabolite of PMA detected was formed via O-270 
demethylation catalysed by CYP enzymes, resulting in a para-hydroxylated metabolite 271 
(PMA-M1) (Table 1 and Fig. 3A). Its molecular ion was m/z 152.1063 with the difference in 272 
mass error between the measured and theoretical mass (i.e. ∆mass) at +4.60 ppm and the 273 
measured DBE value at 4 (Table 1). With different collision energy values applied (Fig. S1), 274 
the molecular structure of PMA-M1 was elucidated through five potential major fragment 275 
ions which were m/z 135.0799, 107.0495, 91.0552, 77.0390 and 65.0364 (Table 1, Fig. S1). 276 
The fragment ion m/z 135.0799 resulted from a loss of NH3 and then was further fragmented 277 
with a loss of C2H4 (ethylene) to yield m/z 107.0495 (C7H7O+). The ion C7H7O+ is likely a 278 
hydroxyl-tropylium ion which possibly facilitates the loss of the hydroxyl group on the 279 
benzyl moiety. The fragment ions m/z 91.0552 (C7H7+, benzylium ion ↔ tropylium ion), 280 
77.0390 (C6H5•+, radical benzene) and 65.0364 (C5H5•+, a loss of CH≡CH from tropylium 281 
ion) represent the hallmark features of the alkylbenzene moiety [27]. Also, PMA-M1 eluted 282 
approximately 10 min earlier than the parent compound, suggesting that it has a higher 283 
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polarity than PMA, in agreement with the formation of a hydroxylated metabolite. PMA-M1 284 
was not detected in any of the three negative control samples, confirming it to be a metabolite 285 
produced by CYP enzymes.  286 
In tier IA samples, two metabolites of PMMA were detected (Table 2). The precursor ion 287 
of the first metabolite (PMMA-M1) was m/z 166.1234 with the measured DBE value at 4, 288 
corresponding to the metabolite resulting from O-demethylation of PMMA catalysed by 289 
CYPs (∆mass= +4.82 ppm) (Table 2, Fig. 3B). The pattern of the MS/MS spectrum of 290 
PMMA-M1 was like that of PMA, suggesting the presence of a hydroxylated group in the 291 
para position of PMMA-M1 as well. The major fragments of PMMA-M1 included the loss of 292 
NH2CH3 for m/z 135.0798 and the loss of NH2CH3 and CH4 for m/z 119.0472 (Table 2, Fig. 293 
S2A). The presence of the alkylbenzene moiety was noticed at m/z 107.0483, 91.0540, 294 
77.0383 and 65.0380 (see above). The precursor ion of the second metabolite (PMMA-M2) 295 
of PMMA was m/z 166.1208 (∆mass= +10.8 ppm) and the measured DBE value at 4 (Table 296 
2), which represented the metabolite produced by N-demethylation of PMMA by CYP 297 
enzymes (Fig. 3B). The structure of PMMA-M2 can be explained by three major product ions 298 
and the feature of the alkylbenzene moiety (Table 2, Fig. S2B). A loss of NH3 for m/z 299 
149.0931 remained the common fragment. This ion was further fragmented with a loss of 300 
CH4 and C2H4 for the product ions m/z 135.0790 and 121.0625, respectively. Both PMMA-301 
M1 and PMMA-M2 eluted several min earlier than PMMA, suggesting that they are more 302 
hydrophilic compounds than PMMA, which is consistent with their postulated structures. 303 
Furthermore, the retention time of PMMA-M2 was same as that of the PMA standard, which 304 
further substantiates its structural identification. Both PMMA-M1 and PMMA-M2 were not 305 
detected in any of the three negative control samples, confirming that both PMMA 306 
metabolites were produced by CYP enzymes.  307 
Conjugated metabolites of PMA, PMMA and of their CYP-mediated metabolites (i.e. 308 
PMA-M1, PMMA-M1 and PMMA-M2) were not detected either in tier IA, nor tier IB 309 
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samples. However, in the positive control samples, 4-NP-GLUC and 4-NP-SULF, 310 
metabolites of 4-NP produced by UGTs and SULTs, respectively, were detected. This result 311 
suggests that the experiment was conducted properly and that both UGTs and SULTs 312 
expressed normal catalytic activity. Therefore, the positive control samples substantiated the 313 
lack of formation of glucuronidated and sulfated metabolites of PMA-M1, PMMA-M1 and 314 
PMMA-M2 under the experimental conditions tested.  315 
PMA-M1 was consistently detected in all tier II samples and not in any of the negative 316 
control samples. There was a clear increasing trend of formation of PMA-M1 with incubation 317 
times, protein concentrations and substrate concentrations (Figs. 4A-C). This confirmed that 318 
PMA-M1 was a metabolite of PMA produced by CYPs. The formation trend of PMA-M1 319 
appeared linked with the reduction of PMA (Figs. 4A-B), providing further evidence of the 320 
biotransformation of PMA to PMA-M1.  321 
Similarly, both metabolites of PMMA identified in tier IA were also detected in the tier 322 
II samples. The amount of both PMMA-M1 and PMMA-M2 increased with the incubation 323 
time, protein concentrations and substrate concentrations (Figs. 4D-F), confirming that 324 
PMMA-M1 and PMMA-M2 were the metabolites of PMMA produced by CYP enzymes. In 325 
contrast, the parent compound showed an opposite (decreasing) trend. Also, under the 326 
different incubation conditions used, PMMA-M1 was formed faster than PMMA-M2 (Figs. 327 
4D-F), suggesting that PMMA-M1 was the primary in vitro metabolite of PMMA. Both 328 
PMMA-M1 and PMMA-M2 were not detected in any of the three negative control samples, 329 
confirming that they were metabolites of PMMA, formed by CYP enzymes. The two data 330 
analysis approaches provided consistent results.  331 
3.2. 4-MTA 332 
In tier IA samples, four metabolites (4-MTA-M1, -M2, -M3 and -M4) formed by CYP 333 
enzymes were detected (Table 3). None of the four metabolites were detected in any of the 334 
three negative control samples. The 4-MTA-M1 precursor ion was m/z 198.0946 (∆mass = -335 
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0.50 ppm) and the measured DBE value at 4, representing a hydroxylated metabolite of 4-336 
MTA (Fig. 3C). The structure of 4-MTA-M1 was further elucidated by its MS/MS spectrum 337 
(Table 3, Fig. S3A). The loss of NH3 and NH2CH2CH3 gave the product ions m/z 181.0674 338 
and 153.0362 respectively. The loss of NH3 followed by that of CH3SH from the molecule 339 
facilitated the equilibrium moiety between ketone and hydroxyl-ethylene for the fragment ion 340 
m/z 133.0639. This was likely to further break the OH and C=C bond readily to produce the 341 
fragment ion m/z 117.0690 and 107.0490, respectively. The characteristic fragment ions for 342 
the alkylbenzene moiety were identified at m/z 91.0544, 77.0382 and 65.0391. The fragment 343 
ions m/z 133.0639 and 107.0490 provided consistent evidence that the hydroxyl group was 344 
located on the alkyl chain rather than on the benzyl ring of 4-MTA. Also, 4-MTA-M1 eluted 345 
about 16 min earlier than 4-MTA, suggesting it was a more polar compound than 4-MTA, 346 
which is consistent with its postulated structure. The precursor ion of 4-MTA-M2 was m/z 347 
168.0836 (∆mass = -2.97 ppm) with the measured DBE value at 4, matched to a thiol 348 
metabolite resulting from S-demethylation of 4-MTA (Table 3). The structure of 4-MTA-M2 349 
was postulated by the product ions m/z 151.0558 possibly due to the loss of NH3, 117.0692 350 
likely due to the loss of NH3 and SH2, and 91.0536 resulting from the formation of 351 
benzylium/tropylium ion (Table 3, Fig. S3B). Also, 4-MTA-M2 eluted about 13 min earlier 352 
than 4-MTA (Table 3), suggesting that it is a more polar compound than the substrate.  353 
The 4-MTA-M3 precursor ion was m/z 197.0633 (∆mass = +1.01 ppm) with a measured 354 
DBE value of 5, and this matched to the metabolite resulting from oxidative deamination of 355 
4-MTA-M1 by CYPs (Table 3, Fig. 3C). The structure of 4-MTA-M3 was postulated by the 356 
fragment ion m/z 197.0631 (Table 3, Fig. S3C). The acyloin function group, α-hydroxyl 357 
ketone, was readily broken to yield the fragment ion m/z 137.0411. After that, the fragment 358 
ions m/z 122.0184 and 121.0095 corresponded to the potential resonance double and triple 359 
bonding between the S and C atom [28]. The fragment ions for the alkylbenzene moiety of 360 
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the 4-MTA-M3 molecule were noticed (Table 3). 4-MTA-M3 eluted about five min later than 361 
4-MTA-M2 (Table 3), suggesting it is a less polar compound than 4-MTA-M2.  362 
The 4-MTA-M4 precursor ion was m/z 199.0787 with the measured DBE value at 4 363 
(Table 3, Fig. S3D), corresponding to a di-hydroxylated metabolite of 4-MTA from reduction 364 
of 4-MTA-M3 (Fig. 3C). The molecular structure of 4-MTA-M4 was similar to that of 4-365 
MTA-M1 and 4-MTA-M3, as suggested by the common fragment ions present in the MS/MS 366 
profiles of these three compounds (Fig. S3). For example, the cleavage of the OH-C=C-OH 367 
and the rearrangement of the C-S bond led to the fragment ions m/z 122.0156, 121.0097 and 368 
107.0491. The loss of SHCH3 from the benzene ring and the dihydroxylated group gave the 369 
fragment ion m/z 117.0712, which was then further fragmented to form benzylium/tropylium 370 
ion m/z 91.0547 and the related radical benzene m/z 77.0375. 4-MTA-M4 eluted about 6 min 371 
earlier than 4-MTA, suggesting it is a more polar compound of 4-MTA due to the addition of 372 
two hydroxylated groups.  373 
Phase II metabolites of 4-MTA and their CYP-mediated metabolites (i.e. 4-MTA-M1, -374 
M2, -M3 or -M4) were not detected neither in tier IA nor tier IB samples, whereas 4-NP-375 
GLUC and 4-NP-SULF were found in the UGT and SULT positive control samples, 376 
respectively. The positive results from the positive control samples supported the lack of 377 
formation of glucuronidated and sulfated metabolites of 4-MTA-M1, -M2, -M3 and -M4 378 
under the experimental conditions used.  379 
In tier II samples, 4-MTA-M1, -M3 and -M4, but not -M2, were detected. These 380 
metabolites were not detected in any of the three negative control samples. The formation of 381 
4-MTA-M1, -M3 and -M4 increased with incubation time, protein concentration and 382 
substrate concentration values used (Fig. 5). In all the analysed samples, 4-MTA-M1 was 383 
consistently formed more quickly than 4-MTA-M4, followed by 4-MTA-M3. This result 384 
suggested that 4-MTA-M1, -M3 and -M4 were the primary, intermediate and tertiary 385 
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metabolite of 4-MTA, respectively, under the range of incubation conditions tested, whereas 386 
4-MTA-M2 was only a minor metabolite of 4-MTA.    387 
3.3. BDB and MBDB  388 
In tier IA samples, no metabolites of BDB produced by CYPs were detected. Only one 389 
metabolite of MBDB was detected (MBDB-M1). Its measured precursor ion was m/z 390 
194.1174 with the DBE value at 5, which matched to the molecular ion of the N-391 
demethylated metabolite of MBDB produced by CYPs (∆mass= +1.03 ppm, Table 4, Fig. 392 
3D). MBDB-M1 was not found in any of the three negative control samples, suggesting that 393 
it was a metabolite of MBDB formed by CYP enzymes. The postulated structure of MBDB-394 
M1 was elucidated by its MS/MS profile (Table 4, Fig. S4). The loss of NH3 from MBDB-395 
M1 ion resulted in the product ion m/z 177.0894 which then results in m/z 135.0447 due to 396 
the loss of the propyl group. With higher collision energy, the dioxolane ring of the MBDB-397 
M1 was broken to form the fragment ions m/z 117.0327 and 105.0329. Again, the feature of 398 
the alkylbenzene moiety with m/z 107.0499, 91.0526 and 77.0391 was detected as the 399 
MS/MS fragment ions of MBDB-M1. Also, MBDB-M1 eluted approximately two min earlier 400 
than MBDB, suggesting that MBDB-M1 was slightly more polar than MBDB, consistent 401 
with its postulated structure. The retention time and the MS/MS fragmentation patterns of 402 
MBDB-M1 were as alike as that of BDB. No glucuronidated and sulfated analogues of 403 
MBDB and MBDB-M1 were detected in both tier IA and IB samples. Detection of 4-NP-404 
GLUC and 4-NP-SULF in positive control samples substantiated the lack of formation of 405 
glucuronidated and sulfated metabolites of MBDB-M1 under the experimental conditions.  406 
MBDB-M1 was detected in all tier II samples, but not found in any of the three negative 407 
control samples. No other MBDB metabolites produced by CYPs were detected, which was 408 
consistent with the results obtained in tier IA. MBDB-M1 formation increased with 409 
incubation times, protein concentrations and substrate concentrations (Fig. 6), providing 410 
further evidence that MBDB-M1 was the (only) metabolite of MBDB formed by CYPs. Since 411 
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no BDB metabolites produced by CYPs were identified in tier I, a tier II experiment was not 412 
conducted for BDB.  413 
3.4. 5-APB and 6-APB 414 
No metabolites of 5-APB and 6-APB produced by CYP, UGT and SULT enzymes were 415 
detected in any tier I samples. Again, 4-NP-GLUC and 4-NP-SULF were respectively 416 
detected in the UGT and SULT positive control samples. Consequently, tier II experiments 417 
were not conducted.  418 
 419 
4. Discussion 420 
This study successfully investigated the formation and characterisation of in vitro 421 
metabolites of seven phenethylamine-based designer drugs using HLM and LC-QTOF-MS. 422 
In tier IA, structures of the possible metabolites were predicted through interpreting the 423 
potential enzymatically-catalysed reactions between the parent drug and the family of 424 
enzymes selected. Since reference standards for the CYP-produced metabolites detected in 425 
tier IA may not be always available from commercial laboratories, the current study included 426 
tier IB experiments, in which these primary metabolites were enzymatically generated and 427 
then incubated with the enzyme mixture containing the Phase II enzyme families (i.e. UGTs 428 
and SULTs). Furthermore, this study presented tier II experiments as an extended approach to 429 
confirm the metabolites identified in tier I, by understanding the formation profiles of the 430 
metabolites according to three different experimental conditions. With such multiple testing 431 
conditions, the work overall provides a comprehensive assessment of the in vitro experiments 432 
for higher reproducibility and consistency of in vitro metabolism data. It should be noted that 433 
careful attention has been paid to the preparation of the reaction mixture in this study: 434 
particularly, (a) the organic solvent content was kept at maximum 1% of the reaction mixture 435 
to minimise its dose-dependent impact on the enzyme catalytic activity [29, 30]; (b) the 436 
NADPH was replenished every hour to counterbalance its deterioration over time and to thus 437 
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maintain its concentration close to saturation [31]; (c) the final protein concentration in each 438 
sample was kept below 1 mg/mL to avoid large extents of non-specific protein binding of the 439 
substrate [32, 33]; (d) a three-hour long incubation was conducted in tier IB to generate 440 
enough Phase I metabolites for further Phase II reactions (Fig. 2); (e) positive and negative 441 
control samples were prepared as quality controls of the experiments for justifying the 442 
obtained results; (f) theophylline (which ionises in both positive and negative modes) was 443 
chosen as the internal standard to compensate variations during sample preparation and 444 
analytical measurements. 445 
This study showed that the in vitro metabolism of PMA and PMMA was relatively slow, 446 
with only one metabolite (para-hydroxyamphetamine) formed from PMA and two 447 
metabolites (primary: para-hydroxymethamphetamine; secondary: PMA) from PMMA. As 448 
they share a phenethylamine moiety, the proposed pathway of PMA and PMMA metabolism 449 
in the present study was in agreement with that of other illicit phenethylamine drugs. For 450 
example, both amphetamine and methamphetamine are not extensively metabolised in 451 
humans (about 30% and 40% of the parent compound is measured in human urine, 452 
respectively) [34]. The primary metabolite of PMA and PMMA (PMA-M1 and PMMA-M1, 453 
respectively) was mainly produced by CYP-mediated O-demethylation. However, this 454 
reaction occurred approximately 10 to 20 times faster for PMMA than for PMA, which was 455 
observed consistently with increasing experimental times, enzyme concentrations, and 456 
substrate concentrations (see red symbols in Fig. 4). Since the structural difference between 457 
PMA and PMMA is only the methylation of the amino group (for PMMA), the obtained data 458 
suggest that the presence of the methylated amino group substantially favoured an O-459 
dealkylation metabolism pathway to produce para-hydroxyl metabolites. Similar results were 460 
also obtained in previous studies when comparing amphetamine and methamphetamine in 461 
vivo metabolism in humans. While the para-hydroxyl metabolite is common for 462 
amphetamine and methamphetamine, its formation is more pronounced for methamphetamine 463 
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than amphetamine (15% vs. 3%, respectively) [34-36]. Moreover, the in vitro metabolism of 464 
PMMA investigated in this study showed that the N-dealkylation reaction was about five to 465 
seven times less favourable than the O-dealkylation (see red and purple symbols in Figs. 4D-466 
F). This is consistent with N-demethylation of methamphetamine to amphetamine (about 4-467 
7% of a methamphetamine dose excreted in urine), occurring only to a very small extent [34].  468 
The metabolites of PMA and PMMA detected in this study are generally consistent with 469 
those reported in the literature. PMA-M1 was the major in vitro metabolite produced by 470 
CYP2D6 [18] and the major in vivo metabolite in urine samples of three healthy volunteers 471 
who consumed PMA [37, 38] (Table S1). Similarly, CYP2D6 has been found to mediate the 472 
in vitro formation of PMMA-M1 in humans [19, 20, 38]. To our knowledge, in vivo 473 
metabolism studies of PMMA are not available for humans, only for rats [39]. In urine 474 
samples collected from rats administered with PMMA, PMMA-M1 and PMMA-M2 were the 475 
major and the minor metabolites detected, respectively (Table S1). This result is in agreement 476 
with the in vitro data of this study, implying a common metabolism pathway of PMMA in 477 
rats and humans.  478 
Glucuronidated PMA-M1 was occasionally detected in the urine samples of the three 479 
volunteers [37] (Table S1). For glucuronidated and/or sulfated metabolites of PMMA, minor 480 
amounts were found in the rat urine [39] (Table S1). Similarly, urinary excretion of 481 
conjugated metabolites for amphetamine and methamphetamine was observed only to a small 482 
extent in humans [34-36]. Taken together, these findings consistently reveal that in vivo 483 
glucuronidation and sulfation is not a major part of the metabolic pathway of PMA and 484 
PMMA in humans and rats. This finding is coherent with the lack of detection of PMA and 485 
PMMA Phase II metabolites in the in vitro metabolism experiments of this study.  486 
This study revealed that 4-MTA was largely metabolised into four metabolites (Table 3) 487 
and a clear trend of their formation was observed (Fig. 5). The results also suggest that the 488 
mechanism of the CYP-mediated metabolism of 4-MTA is different from that of PMA and 489 
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PMMA. The primary metabolite (4-MTA-M1) of 4-MTA is a mono-hydroxylated metabolite 490 
(4-methylthiocathine), most likely formed by oxidation of an unsubstituted C atom, catalysed 491 
by CYPs. In spite of sharing similar chemical structures among 4-MTA, PMA and PMMA, 492 
this mono-hydroxylated metabolite was not detected for PMA or PMMA. This implies that 493 
the presence of the S atom in 4-MTA at the para position of the phenethylamine-based 494 
chemical structure favours such oxidative metabolism rather than the O atom in PMA and 495 
PMMA. To a dealkylation reaction for such para-substituted phenethylamine compounds, the 496 
obtained data reveal that with CYP enzymes, S-dealkylation is much less favourable than O-497 
dealkylation reaction. This was observed from the result that the S-demethylated metabolite 498 
(4-MTA-M2) of 4-MTA was only detected after the three-hour long incubations (the first set 499 
of tier IB), whereas the O-demethylated metabolite of PMA and PMMA were readily 500 
generated after 10 min (Fig. 4). The tier II data of 4-MTA provided an indication that 4-501 
MTA-M1 is transformed by CYPs to the corresponding ketone (4-MTA-M3, secondary or 502 
intermediate metabolite) through an oxidative deamination (Fig. 3C). It is then reduced to a 503 
di-hydroxylated metabolite (4-MTA-M4, tertiary metabolite, Fig. 3C), showing a similar 504 
metabolism pattern to 4-MTA-M1 (see red and green symbols in Fig. 5).  505 
 Even less is known about 4-MTA metabolism than that for PMA and PMMA. 4-506 
Methylthiobenzoic acid was reported as the major metabolite when incubating 4-MTA with 507 
human hepatocytes obtained from three volunteers [40], but this metabolite was not detected 508 
in this study. The discrepancy might be due to the lack of the enzymes for producing 4-509 
methylthiobenzoic acid in HLM. In contrast, unchanged 4-MTA was found as the major 510 
compound in five human urine samples (Table S1) with a few minor metabolites identified 511 
which were formed via oxidative deamination followed by reduction to corresponding 512 
alcohol and degradation of the side change to 4-methylthiobenzoic acid [41]. Metabolites of 513 
ring- and β-hydroxylation (4-methylthiocathine, i.e. 4-MTA-M1 in this study) were detected 514 
in the urine samples too [41]. Similar metabolites were also observed in mice urine samples 515 
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[42] (Table S1), including unchanged 4-MTA, 4-methylthiobenzoic acid, 4-methylthiocathine 516 
and hydroxyl-4-MTA on the aromatic ring and the methylthio-side chain; however, 517 
conjugation of these metabolites was hardly observed. While the identified in vivo and in 518 
vitro metabolites of 4-MTA partly agree with this and previous studies [40-42], the current 519 
study provides additional information on in vitro metabolism of 4-MTA using CYPs.  520 
The obtained in vitro metabolism data on MBDB, BDB, 5-APB and 6-APB by HLM and 521 
HLCYT consistently indicate that these drugs are hardly metabolised. The only metabolite of 522 
MBDB was detected via an N-dealkylation reaction (MBDM-M1; Table 4, Fig. 3D). The 523 
difference in the chemical structure between MBDB and BDB is only the methylation of the 524 
amino group (for MBDB). The data again showed that dealkylation metabolism is more 525 
favourable at the amino than at the methyl group, consistent with what has been noticed for 526 
PMMA metabolism (Figs. 4D-F). The consistent formation pattern between MBDB-M1 and 527 
PMMA-M2 (see red symbols in Fig. 6 and purple symbols in Figs. 4D-F) implies that the N-528 
dealkylation metabolism pathway for such phenethylamine-based designer drugs in general 529 
proceeds at a very slow pace. Furthermore, the lack of detection of any metabolites for BDB, 530 
5-APB and 6-APB reinforces the role of methylation of the amino group in favouring the in 531 
vitro metabolism for this group of drugs as this moiety is the major structural difference 532 
among them.  533 
The results of this study are partially in line with other metabolism studies for these four 534 
drugs. For example, MBDB-M1 (i.e. BDB) was the major metabolite of MBDB in which 535 
CYP2B6 is supposed to mediate this N-demethylation metabolic pathway [21, 22]. Although 536 
the catechol metabolite of MBDB and BDB through mediation of CYP2D6 for demethylation 537 
[22, 23] was detected in the human and rat urine samples [21] (Table S1), this metabolite has 538 
been found to be unstable in the in vitro assays [21, 43]. The lack of detection of the catechol 539 
metabolite for MBDB and BDB in this study could be explained by this previous finding 540 
and/or because its amounts would have been too low in the in vitro samples for the QTOF-541 
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MS detection limit. The latter reason could also explain the lack of detection of N-542 
demethylated metabolite for BDB. The data obtained are consistent with the previous study 543 
showing that glucuronidated and sulfated conjugated metabolites of MBDB and BDB were 544 
not detected in the in vitro experiments using particular isoenzymes of human and rat [21]. 545 
These results overall suggest that conjugation of MBDB and BDB appears not to be a major 546 
part of their metabolic pathway in humans. Human in vitro metabolism studies for 5-APB 547 
and 6-APB are very limited in the literature and thus in vitro metabolites of these drugs are 548 
not yet well-known so far [44]. While this study has found that the metabolism process of 5- 549 
and 6-APB was very slow, one study [45] has very recently shown similar results, in that only 550 
limited amounts of in vitro metabolites of 5-APB, including hydroxyl-5-APB, hydroxy-551 
dihydro-5-APB and 3-carboxymethyl-4-hydroxy amphetamine, were yielded and its 552 
formation rate was very low. In vivo metabolites of 5-APB were recently reported in rat urine 553 
[45] but are not yet known in human urine (Table S1). Similar to the present in vitro study, 5-554 
APB and 6-APB were not degraded by activated sludge (own unpublished data). These 555 
findings suggest that these two drugs are rather resistant to enzymatic and bacterial 556 
digestions.  557 
In vitro metabolism data of the selected designer drugs are important for drug-related 558 
disciplines, such as forensic toxicology, since they provide key compounds useful to better 559 
identify these drugs in humans and crime scenes. Also, the results of the current study reveal 560 
potential human biomarkers of the targeted designer drugs to be measured in urine from 561 
individuals, pooled urine samples or even wastewater samples for assessing the use of these 562 
designer drugs in the emerging research field of wastewater-based drug epidemiology [46]. 563 
Since the data indicated that the in vitro metabolism of the targeted designer drugs proceeds 564 
at slow rate, the parent drug itself appears to be the key biomarker in most cases. However, 565 
for PMA and PMMA, the respective para-hydroxylated metabolite can be considered as its 566 
second target biomarker. Also, it should be noted that since PMMA-M2 (i.e. PMA) was only 567 
24 
 
the secondary metabolite of PMMA, high levels of PMA detection in human fluids and 568 
wastewater samples may reflect the use PMA rather than that of PMMA. From the current in 569 
vitro experiments of 4-MTA, 4-methylthiocathine (4-MTA-M1) can be regarded as its key 570 
biomarker, with the di-hydroxylated metabolite (4-MTA-M4) as its second major biomarker. 571 
In future studies, in vitro experiments can provide further support to identify suitable 572 
biomarkers in the matrix of interest. For this purpose, the database of retention times, MS and 573 
MS/MS spectra of each metabolite detected in vitro represents a valuable tool to confirm the 574 
identity of the biomarkers detected in (in vivo) samples, particularly when no authentic 575 
reference standards for any of these metabolites/biomarkers are commercially available. It 576 
should be noted that further research is needed to examine whether those potential 577 
biomarkers are stable in wastewater before they can be used for reliable monitoring of drug 578 
use in wastewater-based drug epidemiology.   579 
 580 
5. Conclusions 581 
Overall, the work of this study has, for the first time, (a) screened for human in vitro 582 
metabolites of the selected phenethylamine-based designer drugs using an untargeted analysis 583 
of LC-QTOF-MS, and also (b) described a stepwise in vitro experimental design to enhance 584 
the reliability of assessing in vitro drug metabolism. The metabolism of the targeted drugs 585 
was mainly catalysed by CYP enzymes and progressed at relatively slow rate with only 586 
limited number of metabolites formed. The in vitro metabolism pathway of the selected drugs 587 
preferentially proceeded via O-dealkylation followed by N-dealkylation, and to a much 588 
smaller extent, oxidation of unsubstituted carbon atoms and oxidative deamination. The in 589 
vitro metabolism results broadly agreed with the findings of other available metabolism 590 
studies for phenethylamine-based drugs. The current work has established a list of specific in 591 
vitro human metabolites for the targeted drugs which are beneficial to all kinds of drug-592 
related disciplines, such as clinical and forensic toxicology and the emerging research field of 593 
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wastewater-based drug epidemiology, for better detection and monitoring of the use of these 594 
drugs in humans and communities.  595 
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Tables 724 
 725 
Table 1: Postulated structure for PMA metabolite generated from incubation with HLM in tier I. 726 
ID 
Met Precursor ion (MS-TOF)  Product ions
* (MS/MS-TOF)  
 Measured m/z  [M+H]+  
Expected m/z 
(ppm diff.) 
Measured 
DBE  
RT 
(min) 
Measured 
m/z 
Expected m/z 
(ppm diff.) 
Potential fragment structure 
[molecular formula] Proposed structure 
M1 152.1063 [C9H13NO +H]+ 
152.1070 
(+4.60) 4 5.17 135.0799 
135.0810 
(-8.14) 
 
[C9H11O]+ 
 
C9H13NO 
     107.0495 107.0497 (-1.87)  
[C7H7O]+ 
     91.0552 91.0548 (+4.39) 
 
[C7H7]+ 
     77.0390 77.0386 (+5.19) 
 
[C6H5]•+ 
     65.0364 65.0386  (-33.8) 
 
[C5H5]•+ 
ID Met: Identified metabolite; m/z: mass to charge ratio; DBE: double bond equivalents. 
*See Fig. S1 for the MS/MS-TOF spectrum. 
 727 
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Table 2: Postulated structures for PMMA metabolites generated from incubation with HLM in tier I. 728 
ID 
Met Precursor ion (MS-TOF)  Product ions
* (MS/MS-TOF)  
 Measured m/z  [M+H]+  
Expected m/z 
(ppm diff.) 
Measured 
DBE  
RT 
(min) 
Measured 
m/z 
Expected m/z 
(ppm diff.) 
Potential fragment structure 
[molecular formula] Proposed structure 
M1 166.1234 [C10H15NO +H]+ 
166.1226 
(+4.82) 4 5.40 135.0798 
135.0810  
(-8.88) 
 
[C9H11O]+ 
 
 
C10H15NO 
     119.0472 119.0497 (-21.0) 
 
[C8H7O]+ 
     107.0483 107.0497  (-13.1)  
[C7H7O]+ 
     91.0540 91.0548 (-8.79) 
 
[C7H7]+ 
     77.0383 77.0386 (+3.89) 
 
[C6H5]•+ 
     65.0380 65.0386  (-9.23) 
 
[C5H5]•+ 
 
 
 
 
30 
 
M2 166.1208 [C10H15NO +H]+ 
166.1226 
(+10.8) 4 15.6 149.0931 
149.0966 
(-23.5) 
 
[C10H13O]+ 
 
 
C10H15NO 
     135.0790 135.0810 (-14.8) 
 
[C9H11O]+ 
     121.0625 121.0653 (-23.1) 
 
[C8H9O]+ 
     91.0523 91.0548 (-27.5) 
 
[C7H7]+ 
     77.0371 77.0386 (-19.5) 
 
[C6H5]•+ 
     65.0364 65.0386  (-33.8) 
 
[C5H5]•+ 
ID Met: Identified metabolite; m/z: mass to charge ratio; DBE: double bond equivalents.  
*See Figs. S2A and S2B for the MS/MS-TOF spectrum.   729 
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Table 3: Postulated structures for 4-MTA metabolites generated from incubation with HLM in tier I.  730 
ID 
Met Precursor ion (MS-TOF)  Product ions
* (MS/MS-TOF)  
 Measured m/z  [M+H]+  
Expected m/z 
(ppm diff.) 
Measured 
DBE  
RT 
(min) 
Measured 
m/z 
Expected m/z 
(ppm diff.) 
Potential fragment structure 
[molecular formula] Proposed structure 
M1 198.0946 [C10H15NOS +H]+ 
 198.0947  
(-0.50) 4 6.20 181.0674 
181.0687  
(-7.18) 
 
[C10H13OS]+  
 
 
C10H15NOS 
     153.0362 153.0374  (-7.84) 
 
[C8H9OS]+ 
     133.0639 133.0648  (-6.76)  
[C9H9O]••+ 
     117.0690 117.0699 (-7.69) 
 
[C9H9]••+ 
     107.0490 107.0491  (-0.93) 
 
[C7H7O]••+ 
     91.0544 91.0548  (-4.39) 
 
 
32 
 
[C7H7]+ 
     77.0382 77.0386 (-5.19) 
 
[C6H5]•+ 
     65.0391 65.0386  (+7.69) 
 
[C5H5]•+ 
M2 168.0836 [C9H13NS +H]+ 
168.0841  
(-2.97) 4 8.94 151.0558 
151.0581 
(-15.2) 
 
[C9H11S]+ 
 
 
C9H13NS 
     117.0692 117.0699 (-5.98) 
 
[C9H9]••+ 
     91.0536 91.0548 (-13.2) 
 
[C7H7]+ 
M3 197.0633 [C10H12O2S +H]+ 
197.0631 
(+1.01) 5 14.1 137.0411 
137.0425 
(-10.2) 
 
[C8H9S]+ 
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     122.0184 122.0185  (-0.82) 
 
[C7H6S]•+  C10H12O2S 
     121.0095 121.0106  (-9.09) 
 
[C7H5S]•+ 
     89.0389 89.0386 (+3.37) 
 
[C7H5]••+ 
     77.0385 77.0386 (-1.30) 
 
[C6H5]•+ 
     65.0388 65.0386  (+3.08) 
 
[C5H5]•+ 
M4 199.0787 [C10H14O2S +H]+ 
199.0787 
(0.00)  4 15.4 122.0156 
122.0185  
(-23.8) 
 
[C7H6S]•+ 
 
 
C10H14O2S 
     121.0097 121.0106  (-7.44) 
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 731 
732 
[C7H5S]•+ 
     117.0712 117.0699 (+11.1) 
 
[C9H9]••+ 
     107.0491 107.0491  (0.00) 
 
[C7H7O]••+ 
     91.0547 91.0548 (-1.10) 
 
[C7H7]+ 
     77.0375 77.0386 (-14.3) 
 
[C6H5]•+ 
ID Met: Identified metabolite; m/z: mass to charge ratio; DBE: double bond equivalents.  
*See Figs. S3A to 3D for the MS/MS-TOF spectrum.  
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Table 4: Postulated structure for MBDB metabolite generated from incubation with HLM in tier I. 733 
ID 
Met Precursor ion (MS-TOF)  Product ions
* (MS/MS-TOF)  
 Measured m/z  [M+H]+  
Expected m/z 
(ppm diff.) 
Measured 
DBE  
RT 
(min) 
Measured 
m/z 
Expected m/z 
(ppm diff.) 
Potential fragment structure 
[molecular formula] Proposed structure 
M1 194.1174 [C11H15NO2 +H]+ 
194.1176 
(+1.03) 5 18.7 177.0894 
177.0916 
(-12.4) 
 
[C11H13O2]+ 
 
 
C11H15NO2 
     135.0447 135.0446 (+0.74) 
 
[C8H7O2]+ 
     117.0327 117.0335  (-6.84) 
 or 
 
[C8H5O]••+ 
     107.0499 107.0497  (+1.87)  
[C7H7O]+ 
     105.0329 105.0335 (-5.71) 
 or  
 
36 
 
 
[C7H5O]••+ 
     91.0526 91.0548 (-24.2) 
 
[C7H7]+ 
     77.0391 77.0386 (+6.49) 
 
[C6H5]•+ 
ID Met: Identified metabolite; m/z: mass to charge ratio; DBE: double bond equivalents.   
*See Fig. S4 for the MS/MS-TOF spectrum.   734 
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Figures  736 
 737 
 738 
Figure 1: Seven phenethylamine-based designer drugs selected for this study.   739 
 740 
38 
 
 741 
 742 
Figure 2: Schematic flow of the two-tiered approach on human in vitro drug metabolism in this study. P-I: 743 
Phase I; P-II: Phase II; HLM: human liver microsomes; HLCYT: human liver cytosol. The corresponding 744 
family of enzymes (i.e. CYPs, UGTs and SULTs) is described in section 2.2.       745 
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 749 
 750 
Figure 3: Proposed biotransformation pathways of PMA (A), PMMA (B), 4-MTA (C) and MBDB (D) by 751 
human CYP enzymes. 752 
753 
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 754 
Figure 4: Metabolic profiles of PMA and its metabolite (A–C) and PMMA and its metabolites (D–F) under 755 
three different testing conditions (i.e. changes in the experimental times, enzyme concentrations and drug 756 
concentrations) in the tier II experiment. The response presents as the peak area ratio of the metabolites or 757 
parent drug to the internal standards. Note: when testing with the change in experimental times (i.e. A and D), 758 
the enzyme and substrate concentration was kept at 0.8 mg/mL and 10 µM, respectively; when testing with the 759 
change in the enzyme concentrations (i.e. B and E), the substrate concentration was kept at 10 µM and the 760 
experimental time was conducted for 90 min; when testing with the change in the substrate concentrations (i.e. 761 
C and F), the enzyme concentration was kept at 0.8 mg/mL and the experimental time was conducted for 90 762 
min. See Tables 1 and 2 for the molecular structures of the metabolites. 763 
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 768 
Figure 5: Metabolic profiles of 4-MTA and its metabolites under three different testing conditions (i.e. changes 769 
in the experimental times, enzyme concentrations and drug concentrations) in the tier II experiment. The 770 
response presents as the peak area ratio of the metabolites or parent drug to the internal standards. Note: when 771 
testing with the change in experimental times (i.e. A), the enzyme and substrate concentration was kept at 0.8 772 
mg/mL and 10 µM, respectively; when testing with the change in the enzyme concentrations (i.e. B), the 773 
substrate concentration was kept at 10 µM and the experimental time was conducted for 90 min; when testing 774 
with the change in the substrate concentrations (i.e. C), the enzyme concentration was kept at 0.8 mg/mL and 775 
the experimental time was conducted for 90 min. See Table 3 for the molecular structures of the metabolites. 776 
777 
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 778 
Figure 6: Metabolic profiles of MBDB and its metabolite under three different testing conditions (i.e. changes 779 
in the experimental times, enzyme concentrations and drug concentrations) in the tier II experiment. The 780 
response presents as the peak area ratio of the metabolites or parent drug to the internal standards. Note: when 781 
testing with the change in experimental times (i.e. A), the enzyme and substrate concentration was kept at 0.8 782 
mg/mL and 10 µM, respectively; when testing with the change in the enzyme concentrations (i.e. B), the 783 
substrate concentration was kept at 10 µM and the experimental time was conducted for 90 min; when testing 784 
with the change in the substrate concentrations (i.e. C), the enzyme concentration was kept at 0.8 mg/mL and 785 
the experimental time was conducted for 90 min. See Table 4 for the molecular structure of the metabolite.  786 
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